Could Tiny Rivals Make Gilead, Novartis Obsolete In Oncology? – Investor’s Business Daily
Investor’s Business Daily |
Could Tiny Rivals Make Gilead, Novartis Obsolete In Oncology?
Investor’s Business Daily Novartis and Gilead are still in the early stages of launching their respective drugs called Kymriah and Yescarta, which are known as CAR–T drugs. But Cellectis (CLLS) and Crispr Therapeutics (CRSP) — each with a tiny fraction of their rivals' market … |
